KoreaTechToday - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Lists
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Lists
No Result
View All Result
KoreaTechToday - Korea's Leading Tech and Startup Media Platform
No Result
View All Result
Home Aprinoia Therapeutics

Samsung Biologics, Aprinoia Inks Deal to Develop Alzheimer’s Treatment

 1,601 total views,  1 views today

KoreaTechToday Editor by KoreaTechToday Editor
PUBLISHED: March 17, 2020 UPDATED: March 18, 2020
in Aprinoia Therapeutics, Biotech, China, Samsung Biologics
0
samsung-biologics-plant
Samsung Biologics partners with Aprinoia Therapeutics to develop Alzheimer's disease treatment. Photo shows Samsung Biologics' plant located in Songdo, Incheon. / photo courtesy of Samsung Biologics

Samsung Biologics partners with Aprinoia Therapeutics to develop Alzheimer's disease treatment. Photo shows Samsung Biologics' plant located in Songdo, Incheon. / photo courtesy of Samsung Biologics

Samsung Biologics announced on Tuesday that it signed a contract with Aprinoia Therapeutics to develop the Taiwan-based biotech firm’s Alzheimer’s disease treatment.

Aprinoia Therapeutics specializes in diagnostic devices and treatments for neurodegenerative diseases. The bioventure is a pioneer and leader in the development of monoclonal antibodies against the tau protein.

aprinoia-therapeutics-logo
Taiwanese biotech firm Aprinoia Therapeutics

The South Korean biotech firm aims to expand its presence in Taiwan and China with the newly forged partnership. Samsung’s affiliate signed a contract development organization (CDO) deal with Aprinoia Therapeutics to jointly develop an anti-tau monoclonal antibody drug candidate, designed to slow the progression of Alzheimer’s disease.

The tau protein binds and stabilizes the brain cells’ internal structures. For Alzheimer’s patients, however, those tau proteins instead tend to stick to each other, disrupting the healthy brain system.

Samsung Biologics through a statement said that the partnership with Aprinoia covers the full scope of the candidate product’s development phase from cell line development, process development, current Good Manufacturing Practice (cGMP) manufacturing to an investigational new drug (IND) filing support.

Through the CDO, Samsung Biologics would manufacture a clinical sample of the Taiwanese company’s Alzheimer’s treatment pipeline. It would also aid in its application for clinical tests as investigational novel drug.

Kim Tae-han, Samsung Biologics CEO, expressed their excitement over the opportunity to partner with a biotech company with a distinguished global presence amidst the fast-growing bio landscape in Asia. The Korean company looks forward to demonstrating its unique capabilities, scale, and integrated CDO and leading contract manufacturing organization (CMO) services to their valued clients, he added.

CDO

The CDO would help Samsung biologics to effectively boost its portfolio covering mainland China as well as Taiwan. The Samsung affiliate is already in talks with around 20 Chinese biotech companies for additional business agreements.

Samsung Biologics recently injected more resources to promote its CDO business. The company expects the business to grow 15 percent annually over the following years.

Established in 2011, the biotech firm has grown into one of the leading contract-based drugs making companies. It has since carried out 48 CDO projects, which helps venture companies in the biotechnology sector conduct drug development.

What’s your thoughts?
+1
0
+1
0
+1
0
+1
0
+1
0
+1
0
+1
0
Tags: Alzheimer's diseaseAprinoia TherapeuticsbiotechCDOSamsung Biologicstau proteintreatment

Related Posts

Korea to support the domestic biotech sector in generating $76.9 billion by 2030
Samsung Biologics partners with Aprinoia Therapeutics to develop Alzheimer's disease treatment. Photo shows Samsung Biologics' plant located in Songdo, Incheon. / photo courtesy of Samsung Biologics
Biotech

Korea to support the domestic biotech sector in generating $76.9 billion by 2030

June 7, 2023
Celltrion
Samsung Biologics partners with Aprinoia Therapeutics to develop Alzheimer's disease treatment. Photo shows Samsung Biologics' plant located in Songdo, Incheon. / photo courtesy of Samsung Biologics
Biotech

Celltrion to develop oral autoimmune disease treatment with US firm

June 5, 2023
Minister Lee Young at the “The Regulation Breaking for the Korean Bio Startups” at Pangyo Korea Bio Park on May 30
Samsung Biologics partners with Aprinoia Therapeutics to develop Alzheimer's disease treatment. Photo shows Samsung Biologics' plant located in Songdo, Incheon. / photo courtesy of Samsung Biologics
Biotech

Ministry of SMEs and Startups hosts a “Regulation Breaking” event at Korea Bio Park in Pangyo

August 21, 2023
South Korea to ease regulations for data-driven healthcare startups
Samsung Biologics partners with Aprinoia Therapeutics to develop Alzheimer's disease treatment. Photo shows Samsung Biologics' plant located in Songdo, Incheon. / photo courtesy of Samsung Biologics
Biotech

South Korea to ease regulations for data-driven healthcare startups

May 26, 2023
AMSBIO to revolutionize Korea’s diagnostic market with saliva-based cancer diagnosis technology
Samsung Biologics partners with Aprinoia Therapeutics to develop Alzheimer's disease treatment. Photo shows Samsung Biologics' plant located in Songdo, Incheon. / photo courtesy of Samsung Biologics
Biotech

AMSBIO to revolutionize Korea’s diagnostic market with saliva-based cancer diagnosis technology

March 27, 2023
SK Innovation Signs a Deal With Chinese EV Market Player for Battery Supply
Samsung Biologics partners with Aprinoia Therapeutics to develop Alzheimer's disease treatment. Photo shows Samsung Biologics' plant located in Songdo, Incheon. / photo courtesy of Samsung Biologics
Battery

SK Innovation Signs a Deal With Chinese EV Market Player for Battery Supply

September 9, 2021
No Result
View All Result

Most Popular

  • Top South Korean Tech Products to Look Out for in 2021

    0 shares
    Share 0 Tweet 0
  • 5 Best Korean to English Translation Apps

    0 shares
    Share 0 Tweet 0
  • SK Telecom, KT, LG Uplus Start Pre-ordering for Apple’s iPhone SE

    0 shares
    Share 0 Tweet 0
  • Netflix Files Civil Lawsuit Against SK Broadband Over Network Fees

    0 shares
    Share 0 Tweet 0
  • KT Corporation to develop Korea’s Wifi AP Market via Intel MOU

    0 shares
    Share 0 Tweet 0
  • Quantum Security Arrives in South Korea Thanks to SK Broadband

    0 shares
    Share 0 Tweet 0
  • Samsung Unveils 2024 Generative AI Roadmap for Home Appliances

    0 shares
    Share 0 Tweet 0
  • 5 All-Time Best Rom-Com K-Dramas to Watch

    0 shares
    Share 0 Tweet 0
  • Hyundai Introduces Rotator-Cam for Clearer Autonomous Driving

    0 shares
    Share 0 Tweet 0
  • LG StandbyME Go 27LX5 Introduces A Briefcase-Inspired Portable Display

    0 shares
    Share 0 Tweet 0

PRODUCTS

TESSAN Germany France Travel Power Adapter

Lonely Planet Korea 12

Korean Snack Box Variety Pack

OSULLOC Lovely Tea Gift Box Set

TOPICS

  • Naver
  • Kakao
  • Nexon
  • Netmarble
  • NCsoft
  • Samsung
  • Hyundai

FREE NEWSLETTER

FOLLOW US

  • About Us
  • Cookie policy
  • homepage
  • Privacy Policy
  • Terms of Use

Copyright © 2023 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : press@koreatechtoday.com |

No Result
View All Result
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Lists

Copyright © 2023 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : press@koreatechtoday.com |